Treace to Report Third Quarter 2025 Financial Results on November 6, 2025
Treace Medical Concepts (NasdaqGS: TMCI) will release its third quarter 2025 financial results after market close on Thursday, November 6, 2025. Company management will host a conference call at 4:30 PM ET the same day to discuss results and answer questions.
Investors must register to receive dial-in numbers and a unique PIN to join the call. A live webcast and archived replay will be available on the company’s investor relations site at https://investors.treace.com/. Treace also posts investor‑important information regularly in the Investor Relations section of its website.
Treace Medical Concepts (NasdaqGS: TMCI) annunciarà i suoi risultati del terzo trimestre 2025 dopo la chiusura del mercato di giovedì 6 novembre 2025. Il management dell'azienda terrà una conference call alle 4:30 PM ET nello stesso giorno per discutere i risultati e rispondere alle domande.
Gli investitori devono registrarsi per ricevere numeri di accesso e un PIN univoco per partecipare alla chiamata. Una trasmissione in diretta e la replica saranno disponibili sul sito di relazioni con gli investitori dell'azienda all'indirizzo https://investors.treace.com/. Treace pubblica anche regolarmente informazioni importanti per gli investitori nella sezione Investor Relations del proprio sito web.
Treace Medical Concepts (NasdaqGS: TMCI) divulgará sus resultados del tercer trimestre de 2025 después del cierre del mercado el jueves 6 de noviembre de 2025. La dirección de la empresa celebrará una conferencia telefónica a las 4:30 PM ET ese mismo día para discutir los resultados y responder preguntas.
Los inversores deben registrarse para recibir números de acceso y un PIN único para unirse a la llamada. Una transmisión en vivo y la reproducción archivada estarán disponibles en el sitio de relaciones con inversores de la empresa en https://investors.treace.com/. Treace también publica regularmente información importante para inversores en la sección Investor Relations de su sitio web.
Treace Medical Concepts (NasdaqGS: TMCI)는 2025년 3분기 실적을 2025년 11월 6일 목요일 장 마감 후 발표합니다. 회사 경영진은 같은 날 동부 표준시 4:30 PM에 전화회의를 주최하여 실적을 논의하고 질의에 응답합니다.
투자자는 전화 접속 번호와 고유 PIN을 받으려면 등록해야 합니다. 라이브 웹캐스트 및 보관 재생은 회사의 투자자 관계 사이트 https://investors.treace.com/에서 이용할 수 있습니다. Treace는 또한 투자자용 정보가 정기적으로 회사 웹사이트의 Investor Relations 섹션에 게시됩니다.
Treace Medical Concepts (NasdaqGS: TMCI) publiera ses résultats du troisième trimestre 2025 après la clôture du marché le jeudi 6 novembre 2025. La direction de l'entreprise organisera une conférence téléphonique à 16h30 HE le même jour pour discuter des résultats et répondre aux questions.
Les investisseurs doivent s'inscrire pour recevoir des numéros d'accès et un code PIN unique pour rejoindre l'appel. Une webdiffusion en direct et une rediffusion seront disponibles sur le site des relations investisseurs de l'entreprise à l'adresse https://investors.treace.com/. Treace publie également régulièrement des informations importantes pour les investisseurs dans la section Investor Relations de son site internet.
Treace Medical Concepts (NasdaqGS: TMCI) wird die Ergebnisse des dritten Quartals 2025 nach Börsenschluss am Donnerstag, den 6. November 2025 veröffentlichen. Das Management des Unternehmens wird am selben Tag um 4:30 PM ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen und Fragen zu beantworten.
Investoren müssen sich registrieren, um Anrufnummern und eine eindeutige PIN für die Teilnahme zu erhalten. Eine Live-Übertragung und eine archivierte Wiedergabe stehen auf der Investor-Relations-Seite des Unternehmens unter https://investors.treace.com/ zur Verfügung. Treace veröffentlicht auch regelmäßig investorenseitige Informationen im Investor Relations-Bereich seiner Website.
Treace Medical Concepts (NasdaqGS: TMCI) ستصدر نتائجها المالية للربع الثالث من 2025 بعد إغلاق السوق يوم الخميس 6 نوفمبر 2025. ستعقد إدارة الشركة مكالمة مؤتمر في 4:30 مساءً بتوقيت شرق الولايات المتحدة في نفس اليوم لمناقشة النتائج والإجابة على الأسئلة.
يجب على المستثمرين التسجيل للحصول على أرقام الاتصال ورقم تعريف شخصي فريد للانضمام إلى المكالمة. سيكون هناك بث حي وإعادة عرض محفوظة متاحة على موقع علاقات المستثمرين للشركة على https://investors.treace.com/. Treace أيضاً تنشر معلومات هامة للمستثمرين بانتظام في قسم Investor Relations من موقعها الإلكتروني.
Treace Medical Concepts (NasdaqGS: TMCI) 将于2025年第三季度财务业绩在市场收盘后披露，时间为2025年11月6日，星期四。公司管理层将在同一天举行一个电话会议，时间为东部时间下午4:30，以讨论业绩并回答问题。
投资者必须注册以获取拨入号码和唯一的PIN以加入电话会议。现场网络广播和存档回放将通过公司投资者关系网站在https://investors.treace.com/提供。Treace还会定期在其网站的投资者关系部分发布对投资者重要的信息。
- None.
- None.
PONTE VEDRA, Fla., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the third quarter 2025 after the close of trading on Thursday, November 6, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.
Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.treace.com/.
Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.
About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of bunion surgeons and address the four classes of bunions, Treace introduced its Adductoplasty® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP® Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty® 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System. Treace continues to expand its footprint in the foot and ankle market with the introduction of its SpeedPlate® Rapid Compression Implants, an innovative fixation platform with broad versatility across Lapiplasty®, Adductoplasty® and SpeedMTP® procedures, as well as other common bone fusion procedures of the foot. For more information, please visit www.treace.com.
To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.
Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net
FAQ
When will Treace (TMCI) report third quarter 2025 results?
What time is the Treace (TMCI) Q3 2025 conference call on November 6, 2025?
How can investors join the Treace (TMCI) Q3 2025 earnings call?
Where can I watch the Treace (TMCI) Q3 2025 webcast or replay?
Does Treace (TMCI) post investor updates outside earnings calls?
